• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Pediatr Gastroenterol Nutr . Higher incidence of paediatric autoimmune liver disease post-COVID

tetano

Editor, Senior Moderator
J Pediatr Gastroenterol Nutr

. 2026 Nov 17.
doi: 10.1002/jpn3.70661. Online ahead of print.

Higher incidence of paediatric autoimmune liver disease post-COVID​


Suz Warner 1 2 , Marumbo Paul Mtegha 1 , Mariana Kostova 1 , Kavitha Jayaprakash 1 , Palaniswamy Karthikeyan 1 , Penny North-Lewis 1 , Sanjay Rajwal 1

Affiliations Expand


Abstract​


Objectives: A higher incidence of autoimmune conditions with greater disease severity is reported post-Coronavirus Disease (COVID). The incidence and disease severity of paediatric autoimmune liver disease (AILD) post-COVID has not been assessed.


Methods: Data on children <16 years of age diagnosed with AILD between 2015 and 2024 from a United Kingdom quaternary liver specialist centre was captured. Comparison of AILD incidence and presenting clinical characteristics in pre and post-COVID pandemic time-periods were made.


Results: 199 patients were newly diagnosed with AILD within the study period (82 pre-COVID [2015-2019]; 47 autoimmune hepatitis type 1 [AIH-1], 11 AIH-2, 9 primary sclerosing cholangitis [PSC], 15 overlap/autoimmune sclerosing cholangitis [ASC], and 117 post-COVID [2020-2024]; 64 AIH-1, 10 AIH-2, 20 PSC, 23 overlap/ASC). A sharp rise in the incidence of AIH-1, PSC and overlap syndrome/ASC was observed post-COVID, being most marked in the AIH-1 cohort (p < 0.0001). Children were older at disease presentation for AIH-1, PSC and overlap/ASC compared to pre-COVID, particularly in AIH-1 (p = 0.0093). Minimal variation was observed in AIH-2 patients. Most patients presenting with AIH-1 and overlap/ASC post-COVID did not have a personal history of autoimmunity. High viral coinfection rates were observed in post-COVID AIH-1 and AIH-2 presentations.


Conclusion: The higher incidence and older presenting age of newly diagnosed AILD patients post-COVID may have resulted from immune dysregulation in susceptible children following the sudden exposure to viral infections after long periods of social isolation, triggering the onset of autoimmunity even in individuals without an autoimmune predisposition.

Keywords: AILD; autoimmune hepatitis; children; immune dysregulation; primary sclerosing cholangitis.
 
Back
Top Bottom